February 28, 2017 / 6:01 PM / 5 months ago

BRIEF-ASIT Biotech reports results of phase III clinical trial

1 Min Read

Feb 28 (Reuters) - ASIT Biotech SA:

* Reports positive results in its phase III clinical trial with gp-ASIT+ for grass pollen induced allergic rhinitis

* Says results allow further discussions with regulatory agencies in Germany and the US regarding gp-ASIT+ clinical development

* First ever clinical study to demonstrate the clinical efficacy of allergen peptides in a real-life setting Source text: bit.ly/2mBnTyr Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below